COVID-19 Disease and Vaccine Status In Tuberculosis Patients In Sakarya

Abstract

Tuberculosis was the leading cause of death worldwide before COVID-19. The present study aimed to examine the cases of COVID-19 disease and vaccination against COVID-19 in patients receiving tuberculosis treatment in Sakarya. In this descriptive study, 132 people aged 18 years and over, registered in Sakarya Tuberculosis Dispensary and continuing treatment in 2021, were included. Cases of COVID-19, hospitalization, intensive care unit (ICU) status and vaccination status against COVID-19 were recorded. Statistical significance level was accepted as p<0.05. The mean age of the patients was 49.8±20.6 years. 65.2% of the patients were male (n=86). It has been determined that 21.2% (n=28) of the patients have been diagnosed with COVID19. No statistically significant difference was observed between the patients' gender and history of COVID-19 infection with mortality (p>0.05). There was no statistically significant difference between the ages of groups with and without COVID-19 (p>0.05). Age was statistically significantly different in the surviving and deceased groups (p<0.05). There was a statistically significant difference between the vaccination status of the patients and mortality (p<0.05).People being treated for tuberculosis are at risk as long as the danger of COVID-19 continues. More emphasis should be placed on the importance of vaccination against COVID-19, especially in elderly individuals receiving tuberculosis treatment.

Keywords

• COVID-19
• tuberculosis
• vaccination
• mortality

References

1. 1. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12;94(1):91-5.
2. 2. Weekly epidemiological update on COVID-19 - 16 November 2022 (İnternet) Avaliable from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---16-november-2022
3. 3. World Health Organization. Global tuberculosis report 2020, (İnternet) 2020. Available from: https://www.who.int/publications/i/item/9789240013131
4. 4. Sarınoğlu RC, Sili U, Eryuksel E, Yildizeli SO, Cimsit C, Yagci AK. Tuberculosis and COVID-19: An overlapping situation during pandemic. The Journal of Infection in Developing Countries. 2020 Jul 31;14(07):721-5.
5. 5. Walaza S, Tempia S, Dawood H, Variava E, Moyes J, Cohen AL, et al. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010–2011. BMC Infectious Diseases. 2015 Jan 27;15(1)
6. 6. Yousaf Z, Khan AA, Chaudhary HA, Mushtaq K, Parengal J, Aboukamar M, et al. Cavitary pulmonary tuberculosis with COVID-19 coinfection. IDCases. 2020;22:e00973
7. 7. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020 May 1;55(5).
8. 8. Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu C, Fan L, Wang X, Cheng M, Bi L, Liu Y. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020 Jan 1

9. 9. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID‐19 severity and mortality: A rapid systematic review and meta‐analysis. Journal of medical virology. 2021 Jan 1
10. 10. Jeon CY, Murray MB. Correction: diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS medicine. 2008 Aug;5(8):e181.
11. 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62.
12. 12. Visca D, Ong CW, Tiberi S, Centis R, D’ambrosio L, Chen B, Mueller J, Mueller P, Duarte R, Dalcolmo M, Sotgiu G. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021 Mar 1;27(2):151-65.
13. 13. Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal. 2020 Jul 1;56(1).
14. 14. Motta I, Centis R, D’Ambrosio L, García-García JM, Goletti D, Gualano G, Lipani F, Palmieri F, Sánchez-Montalvá A, Pontali E, Sotgiu G. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020 Jul 1;26(4):233-40.
15. 15. Roghani A. The influence of Covid-19 vaccine on daily cases, hospitalization, and death rate in Tennessee: a case study in the United States. medRxiv. 2021 Jan 1.
16. 16. Xu S, Huang R, Sy LS, Glenn SC, Ryan DS, Morrissette K, Shay DK, Vazquez-Benitez G, Glanz JM, Klein NP, McClure D. COVID-19 vaccination and Non–COVID-19 mortality risk—seven integrated health care organizations, United States, December 14, 2020–July 31, 2021. Morbidity and Mortality Weekly Report. 2021 Oct 10;70(43):1520.
17. 17. TC Sağlık Bakanlığı, Tüberküloz Tanı ve Tedavi Rehberi (Internet) 2022 [updated 2022 Nov 30; cited 2022 Nov 30]. Available from:https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz_db/haberler/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf
18. 18. T.C Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu Temaslı Takibi, Salgın Yönetimi, Evde Hasta İzlemi ve Filyasyon (Internet) 2022 [updated 2022 Nov 30; cited 2022 Nov 30]. Avaliable from: https://covid19.saglik.gov.tr/Eklenti/42333/0/covid-19gunceldonemdecovid19iliskiliizolasyonvekarintinauygulamalari-2pdf.pdf
19. 19. Öztürk FÖ, Öztomurcuk D, Turan N, Oruç MA. COVID-19 Pandemi Sürecinde Tüberküloz Tanısı Alan Hastaların Deneyimleri: Nitel Araştırma. Sürekli Tıp Eğitimi Dergisi.;31(3):193-200.
20. 20. Otlu B, Yakupoğulları Y, Tanrıverdi ES, Bentli R. Tüberküloz hastalarında gelişen COVID-19’un klinik özellikleri. Mikrobiyol Bul 2022;56(4):722-728.
21. 21. Karaca B. Erişkin yaş grubunda Covid-19 klinik bulguları. Journal of Biotechnology and Strategic Health Research. 2020;4:85-90.
22. 22. Teker AG, Emecen AN, Girgin S, Şimşek-Keskin H, Şiyve N, Sezgin E, Başoğlu E, Yıldırım-Karalar K, Appak Ö, Zeka AN, Ömeroğlu G. Türkiye'de Bir Üniversite Hastanesinde COVID-19 Olgularının Epidemiyolojik Özellikleri. Klimik Journal/Klimik Dergisi. 2021 Apr 1;34(1).
23. 23. Gül Ş, Akalın Karaca ES, Özgün Niksarlıoğlu EY, Çınarka H, Uysal MA. Coexistence of tuberculosis and COVID-19 pneumonia: A presentation of 16 patients from Turkey with their clinical features. Tuberk Toraks 2022;70(1):8-14.
24. 24. T.C Sağlık Bakanlığı Genel Koronavirus Tablosu 2022 (Internet) Avaliable from: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
25. 25. Nabity SA, Han E, Lowenthal P, Henry H, Okoye N, Chakrabarty M, Chitnis AS, Kadakia A, Villarino E, Low J, Higashi J. Sociodemographic characteristics, comorbidities, and mortality among persons diagnosed with tuberculosis and covid-19 in close succession in California, 2020. JAMA network open. 2021 Dec 1;4(12):e2136853-.
26. 26. Song WM, Zhao JY, Zhang QY, Liu SQ, Zhu XH, An QQ, Xu TT, Li SJ, Liu JY, Tao NN, Liu Y. COVID-19 and tuberculosis coinfection: an overview of case reports/case series and meta-analysis. Frontiers in medicine. 2021 Aug 24;8:657006.
27. 27. T.C Sağlık Bakanlığı COVID-19 Aşısı Bilgilendirme Platformu (Internet) 2022 [updated 2022 Nov 30; cited 2022 Nov 30]. Avaliable from: https://covid19asi.saglik.gov.tr/